Eduard Kraychik, MD
Psychiatry · Philadelphia, PANPI 1689611196
Payments from drug & device makers
Across 92 payments — averaging $148.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$11K
- Otsuka America Pharmaceutical, Inc.$578
- Axsome Therapeutics, Inc.$496
- AbbVie$429
- Amneal Pharmaceuticals LLC$143
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$142
- plus $608 from 7 others
What the payments were for
- Consulting fees$6685%
- Speaking & faculty fees$10,50077%
- Travel & lodging$1801%
- Food & beverage$2,27217%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 26 | $11,225 |
| Otsuka America Pharmaceutical, Inc. | 4 | $578 |
| Axsome Therapeutics, Inc. | 16 | $496 |
| AbbVie(2 entities) | 12 | $429 |
| Amneal Pharmaceuticals LLC | 1 | $143 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $142 |
| Novo Nordisk | 2 | $142 |
| Johnson & Johnson(2 entities) | 4 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Pfizer | 5 | $80 |
| Acadia Pharmaceuticals Inc | 6 | $78 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Lundbeck LLC | 3 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUEDEXTA$10,713
- ABILIFY MYCITE$525
- VRAYLAR$248
- Auvelity$221
How this compares
$13,621 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LatudaLurasidone Hcl | 11 | $15,353 |
| Temazepam | 17 | $2,663 |
| Escitalopram Oxalate | 153 | $1,897 |
| Aripiprazole | 42 | $1,408 |
| Trazodone Hcl | 101 | $1,403 |
| Bupropion XlBupropion Hcl | 58 | $1,357 |
| Mirtazapine | 129 | $1,186 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 89 | $1,048 |
| Quetiapine Fumarate | 71 | $963 |
| Sertraline Hcl | 65 | $507 |
| Olanzapine | 36 | $447 |
| Bupropion Hcl SrBupropion Hcl | 42 | $434 |
| Clonazepam | 75 | $424 |
| Paroxetine Hcl | 14 | $376 |
| Fluoxetine Hcl | 24 | $332 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Philadelphia
- Steven ArnoldPhiladelphia$4.1M
- Michael ThasePhiladelphia$2.2M
- Daniel WeintraubPhiladelphia$647K
- Yvette ShelinePhiladelphia$442K
- Kyle KampmanPhiladelphia$355K
- Christian KohlerPhiladelphia$172K
- Freddy AliPhiladelphia$107K
- Stanley CaroffPhiladelphia$105K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.